

City of Mississauga
Corporate Report



<p>Date: October 26, 2021</p> <p>To: Mayor and Members of Council</p>	<p>Originator's files:</p>
<p>From: Paul Mitcham, P.Eng, MBA, City Manager and Chief Administrative Officer</p>	<p>Meeting date: November 10, 2021</p>

Subject

Mississauga Type 2 Diabetes Prevention Strategy – Declaration and Relationship Agreement

Recommendation

1. That the Corporate Report titled “Mississauga Type 2 Diabetes Prevention Strategy,” dated October 26, 2021, from the City Manager and Chief Administrative Officer, be received;
2. That Council sign the Urban Diabetes Declaration as a demonstration of the City’s commitment to developing a Type 2 Diabetes Prevention Strategy for Mississauga; and
3. That the City Manager and the City Clerk be authorized to execute a Relationship Agreement between The Corporation of the City of Mississauga and Novo Nordisk Canada Inc., including any amending agreements and ancillary documents to outline roles and responsibilities in collaborating on the Cities Changing Diabetes Programme, in a form satisfactory to Legal Services.

Executive Summary

- On June 9, 2021, General Committee recommended that the City of Mississauga become a member of the Cities Changing Diabetes Programme (CCD)
- CCD is a program led by the Steno Diabetes Center Copenhagen, University College London and Novo Nordisk to address the growth of type 2 diabetes and obesity
- A Mississauga version of the Urban Diabetes Declaration has been prepared for Council’s consideration and signing
- By signing the Declaration, Council confirms its commitment to reduce Type 2 diabetes and obesity in Mississauga, to develop a Type 2 Diabetes Prevention Strategy and promote awareness of World Diabetes Day on November 14, 2021
- Staff recommend that the City, through the City Manager and City Clerk, enter into a Relationship Agreement with Novo Nordisk to outline roles and responsibilities in

Council	2021/10/26	2
---------	------------	---

collaborating on the CCD Programme

Background

Council approved General Committee recommendation GC-0331-2021 on June 16, 2021, to support the City of Mississauga becoming a member of the Cities Changing Diabetes (CCD) Programme. Mississauga has the second highest rate of diabetes in Peel.

The corporate report titled “Cities Changing Diabetes Programme,” dated May 6, 2021 (Appendix 1), states that the City will be the first Canadian City to sign the Urban Diabetes Declaration. All cities participating in the CCD Programme have signed the declaration signalling a commitment to the five guiding principles to accelerate action to prevent Type 2 diabetes. The five principles are:

1. Invest in the promotion of health and well-being
2. Address social and cultural determinants and strive for health equity
3. Integrate health into all policies
4. Engage communities to ensure sustainable health solutions
5. Create solutions in partnerships across sectors

Comments

By signing the Declaration (Appendix 2), Council confirms its’ commitment to diabetes prevention and to the development of a Mississauga Type 2 Diabetes Prevention Strategy. The signing of the Declaration on November 10, 2021 also aligns with World Diabetes Day, November 14, 2021. World Diabetes Day is recognized every year on November 14, the birthday of Sir Frederick Banting, who co-discovered insulin along with Charles Best in 1922 at a University of Toronto laboratory.

As the City launches into the multi-year CCD Programme, staff recommend that a Relationship Agreement be executed with Novo Nordisk to outline roles and responsibilities within the collaboration. Novo Nordisk is headquartered in Denmark, and has an office in Mississauga. Their staff have been working with City staff on this collaboration for over a year.

The Relationship Agreement between the City and Novo Nordisk will address matters such as:

- scope and objective of the “relationship” to assist the City in understanding the Type 2 diabetes challenge in Mississauga; set goals and timelines for halting the increase of Type 2 diabetes and to work across sectors and disciplines to unite stakeholders in a quest to reduce Type 2 diabetes
- the City’s use of CCD resources and programme tools for project research and community engagement
- how and what information will be shared between the City and Novo Nordisk, and its application

Council	2021/10/26	3
---------	------------	---

- roles and responsibilities for community and stakeholder engagement
- roles and responsibilities for communication and marketing of the City's participation in the CCD Programme.

Strategic Plan

Signing the Urban Diabetes Declaration demonstrates Council's commitment to healthy and connected communities aligned with the Connect pillar of the Strategic Plan.

Financial Impact

There is no financial impact associated with the recommendations of this report. Any future costs related to working in collaboration with the CCD Programme will be covered through approved City operational budgets and Novo Nordisk as outlined in the Relationship Agreement.

Conclusion

The launch of the City's participation in the CCD Programme through the signing of the Urban Diabetes Declaration is a significant milestone demonstrating the City's commitment to Type 2 diabetes prevention. It is appropriate to align this milestone with World Diabetes Day on November 14. The recommended Relationship Agreement will enable a seamless collaboration with the CCD Programme.

Attachments

Appendix 1: Corporate report, "Cities Changing Diabetes Programme," dated May 6, 2021

Appendix 2: Mississauga's Urban Diabetes Declaration



Paul Mitcham, P.Eng, MBA, City Manager and Chief Administrative Officer

Prepared by: Ruth M. Marland, MCIP, RPP, Strategic Leader, Engagement